Abstract
Hemophagocytic lymphohistiocytosis (HLH) is a clinical syndrome in which a large number of inflammatory cytokines, such as IL-6, TNF-α, and sCD25, are released into the blood circulation due to cytotoxic killing cells and dysfunction of natural killer (NK) cells. HLH can be induced by various infections, cancer, or hereditary disorders. HLH is usually fatal due to severe cytopenia and multiple organ failure. Nasal type extranodal natural killer/T-cell lymphoma (ENKTCL) is an aggressive non-Hodgkin’s lymphoma that is closely related to Epstein-Barr virus. ENKTCL can be complicated by HLH at initial diagnosis and recurrence. However, the optimal treatment strategies for ENKTCL-associated HLH are not well defined. Here, we report a case of ENKTCL-associated HLH that was successfully treated with liposomal doxorubicin, etoposide, methylprednisolone, and pegaspargase (DEPL regimen), followed by immunotherapy. This report aims to contribute to improved recognition, diagnosis, and treatment of lymphoma-associated HLH. Keywords: Hemophagocytic lymphohistiocytosis, extranodal natural killer/T-cell lymphoma, liposomal doxorubicin, pegaspargase, lymphoma-associated HLH
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
